Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06607406

Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery

Led by Wake Forest University Health Sciences · Updated on 2026-01-20

75

Participants Needed

3

Research Sites

258 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to determine whether accelerated radiotherapy (involving 6 treatments per week) is better than standard radiotherapy (involving 5 treatments per week) at treating cancer of the head and neck when initiated more than 6 weeks after surgery.

CONDITIONS

Official Title

Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Pathologically confirmed head and neck squamous cell carcinoma of the oral cavity, oropharynx, larynx, hypopharynx, sinus, or lymph nodes of the neck of unknown primary.
  • Planned for curative intent postoperative radiotherapy based on pathologic risk factors.
  • For non-HPV-mediated oropharyngeal or non-oropharyngeal squamous cell carcinoma, presence of at least one risk factor: pathologic tumor classification pT3-4, multiple lymph nodes involved, perineural invasion, lymphovascular invasion, close margins (within 2 mm for oropharyngeal cancer post transoral resection; within 5 mm for others) or cleared margins, extranodal extension, or positive surgical margins.
  • For HPV-mediated oropharyngeal squamous cell carcinoma, presence of at least one risk factor: extranodal extension, positive surgical margins, or more than 4 lymph nodes involved.
  • Complete macroscopic surgical resection with curative intent.
  • Time from primary surgical resection to planned start of postoperative radiotherapy is more than 42 days but less than or equal to 112 days.
  • Age 18 years or older at enrollment.
  • ECOG performance status of 0-1.
  • Ability and willingness to understand and sign informed consent in English or Spanish and complete study-related activities.
Not Eligible

You will not qualify if you...

  • Recurrent head and neck cancer after prior definitive radiotherapy or surgery followed by postoperative radiotherapy or chemoradiotherapy.
  • Second primary head and neck cancer after prior treatment.
  • Prior radiotherapy to the head and neck that overlaps with planned treatment area.
  • Active malignancy other than the head and neck cancer being treated, excluding non-melanoma skin cancer and in situ carcinoma.
  • Metastatic disease beyond the head and neck region.
  • Time from primary surgery to planned postoperative radiotherapy start greater than 112 days.
  • Uncontrolled illness such as active infection, heart failure, unstable angina, arrhythmia, or psychiatric/social conditions limiting compliance.
  • Not a candidate for radiation therapy, including pregnancy or other contraindications.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Levine Cancer Institute

Charlotte, North Carolina, United States, 28204

Actively Recruiting

2

Wake Forest Baptist Comprehensive Cancer Center

Winston-Salem, North Carolina, United States, 27157

Actively Recruiting

3

Advocate Aurora Radiation Oncology

Milwaukee, Wisconsin, United States, 53215

Actively Recruiting

Loading map...

Research Team

R

Ryan Hughes, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here